SG11202007450XA - Cancer therapeutic targeting using mutant p53-specific sirnas - Google Patents

Cancer therapeutic targeting using mutant p53-specific sirnas

Info

Publication number
SG11202007450XA
SG11202007450XA SG11202007450XA SG11202007450XA SG11202007450XA SG 11202007450X A SG11202007450X A SG 11202007450XA SG 11202007450X A SG11202007450X A SG 11202007450XA SG 11202007450X A SG11202007450X A SG 11202007450XA SG 11202007450X A SG11202007450X A SG 11202007450XA
Authority
SG
Singapore
Prior art keywords
mutant
cancer therapeutic
therapeutic targeting
specific sirnas
sirnas
Prior art date
Application number
SG11202007450XA
Other languages
English (en)
Inventor
Kanaga Sabapathy
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11202007450XA publication Critical patent/SG11202007450XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202007450XA 2018-02-21 2019-02-21 Cancer therapeutic targeting using mutant p53-specific sirnas SG11202007450XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201801432S 2018-02-21
PCT/SG2019/050099 WO2019164451A1 (en) 2018-02-21 2019-02-21 Cancer therapeutic targeting using mutant p53-specific sirnas

Publications (1)

Publication Number Publication Date
SG11202007450XA true SG11202007450XA (en) 2020-09-29

Family

ID=67687981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007450XA SG11202007450XA (en) 2018-02-21 2019-02-21 Cancer therapeutic targeting using mutant p53-specific sirnas

Country Status (8)

Country Link
US (1) US12508277B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755802A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021514195A (cg-RX-API-DMAC7.html)
KR (1) KR102741498B1 (cg-RX-API-DMAC7.html)
CN (1) CN111727254B (cg-RX-API-DMAC7.html)
CA (1) CA3090220A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007450XA (cg-RX-API-DMAC7.html)
WO (1) WO2019164451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755802A4 (en) 2018-02-21 2021-11-17 Singapore Health Services Pte Ltd THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
CN115820636B (zh) * 2022-09-02 2024-06-11 华南农业大学 靶向TP53基因的sgRNA及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP3755802A4 (en) 2018-02-21 2021-11-17 Singapore Health Services Pte Ltd THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS

Also Published As

Publication number Publication date
EP3755802A4 (en) 2021-11-17
US12508277B2 (en) 2025-12-30
WO2019164451A1 (en) 2019-08-29
CA3090220A1 (en) 2019-08-29
JP2023096009A (ja) 2023-07-06
EP3755802A1 (en) 2020-12-30
WO2019164451A8 (en) 2020-11-26
CN111727254A (zh) 2020-09-29
JP2021514195A (ja) 2021-06-10
JP2025093992A (ja) 2025-06-24
CN111727254B (zh) 2024-12-17
US20200397813A1 (en) 2020-12-24
KR20200123165A (ko) 2020-10-28
JP7648675B2 (ja) 2025-03-18
KR102741498B1 (ko) 2024-12-11

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
IL280622A (en) Microrna-based therapy targeted against lcp-1 positive cancers
ZA202005847B (en) Cancer therapy
GB201804255D0 (en) Macrophage-based therapy
IL291486B1 (en) Therapeutic conjugates
GB201818110D0 (en) Monocytes for cancer targeting
IL282093B1 (en) Combination therapy for cancer
GB201819853D0 (en) Therapy
GB201905780D0 (en) Cancer therapy
IL279685A (en) Gene therapy
IL263905A (en) Combined cancer treatment
EP3576746A4 (en) THERAPEUTICS AGAINST CANCER
EP3864039A4 (en) Neuroendocrine cancer targeted therapy
GB2580963B (en) Cancer therapies
SG11202012401RA (en) Combination therapy
GB201802326D0 (en) Gene therapy
GB201817470D0 (en) Gene therapy
GB201817385D0 (en) Therapy
GB201704909D0 (en) Cancer therapy
GB201906864D0 (en) Combination therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201711855D0 (en) Cancer therapy
EP4054628A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201901368D0 (en) Cancer therapy